186 related articles for article (PubMed ID: 27434293)
1. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
2. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
Chen Y; Yan H; Wang Y; Shi Y; Dai G
Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
[TBL] [Abstract][Full Text] [Related]
3. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
4. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
[TBL] [Abstract][Full Text] [Related]
5. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
6. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
[TBL] [Abstract][Full Text] [Related]
7. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio.
Bhatti I; Peacock O; Lloyd G; Larvin M; Hall RI
Am J Surg; 2010 Aug; 200(2):197-203. PubMed ID: 20122680
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
[TBL] [Abstract][Full Text] [Related]
9. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Kaneko M; Nozawa H; Sasaki K; Hongo K; Hiyoshi M; Tada N; Murono K; Nirei T; Kawai K; Sunami E; Tsuno NH; Kitayama J
Oncology; 2012; 82(5):261-8. PubMed ID: 22538399
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
Guo J; Wu M; Guo L; Zuo Q
Bull Cancer; 2018 Feb; 105(2):146-154. PubMed ID: 29290332
[TBL] [Abstract][Full Text] [Related]
11. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy.
Luo G; Guo M; Liu Z; Xiao Z; Jin K; Long J; Liu L; Liu C; Xu J; Ni Q; Yu X
Ann Surg Oncol; 2015 Feb; 22(2):670-6. PubMed ID: 25155401
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
[TBL] [Abstract][Full Text] [Related]
13. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma.
Abe T; Amano H; Kobayashi T; Hanada K; Nakahara M; Ohdan H; Noriyuki T
Eur J Surg Oncol; 2018 Oct; 44(10):1573-1579. PubMed ID: 29807728
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy.
Teo M; Mohd Sharial MS; McDonnell F; Conlon KC; Ridgway PF; McDermott RS
Tumori; 2013; 99(4):516-22. PubMed ID: 24326841
[TBL] [Abstract][Full Text] [Related]
17. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC).
Tao L; Zhang L; Peng Y; Tao M; Li G; Xiu D; Yuan C; Ma C; Jiang B
Oncotarget; 2016 Nov; 7(45):74314-74324. PubMed ID: 27494847
[TBL] [Abstract][Full Text] [Related]
18. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
